| 1 |
34403130 | Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts. | 2022 Feb |
1 |
| 2 |
35169154 | A population study of clinically actionable genetic variation affecting drug response from the Middle East. | 2022 Feb 15 |
1 |
| 3 |
35543701 | Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial. | 2022 Jun |
1 |
| 4 |
33277702 | Statin-induced rhabdomyolysis from azithromycin interaction in a patient with heterozygous SLCO1B1 polymorphism. | 2021 Jun |
2 |
| 5 |
33280091 | Physiologically Based Precision Dosing Approach for Drug-Drug-Gene Interactions: A Simvastatin Network Analysis. | 2021 Jan |
1 |
| 6 |
34114646 | Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin. | 2021 Sep |
1 |
| 7 |
34606062 | Role of Drug-Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity. | 2021 Nov |
3 |
| 8 |
34674552 | Prevalence of protective haplotypes of the SLCO1B1 gene for statin transport in Mexican populations. | 2021 Sep |
1 |
| 9 |
31952675 | Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. | 2020 Jan |
1 |
| 10 |
33270123 | Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol: A Randomized Clinical Trial. | 2020 Dec 1 |
5 |
| 11 |
30193394 | The Association between Genetic Polymorphisms and Simvastatin-Induced Myopathy: A Narrative Synthesis of Evidence. | 2019 Apr |
1 |
| 12 |
31173123 | Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users. | 2019 Jun 5 |
1 |
| 13 |
29255993 | Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining. | 2018 Apr |
1 |
| 14 |
29469964 | Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. | 2018 Jun |
1 |
| 15 |
30250148 | Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. | 2018 Dec |
1 |
| 16 |
30336686 | Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia. | 2018 Dec |
4 |
| 17 |
27052517 | Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. | 2017 Jan |
1 |
| 18 |
27168098 | Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. | 2017 Jul |
1 |
| 19 |
28350522 | The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition. | 2017 Apr |
5 |
| 20 |
29181084 | Clinical pharmacogenomics: patient perspectives of pharmacogenomic testing and the incidence of actionable test results in a chronic disease cohort. | 2017 Sep |
1 |
| 21 |
27307760 | The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia. | 2016 |
1 |
| 22 |
27539103 | Large copy-number variations in patients with statin-associated myopathy affecting statin myopathy-related loci. | 2016 Dec 13 |
1 |
| 23 |
27606156 | Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis. | 2016 |
1 |
| 24 |
25379722 | Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort. | 2015 Jan |
1 |
| 25 |
25673568 | Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? | 2015 Mar |
1 |
| 26 |
25992810 | SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. | 2015 May 20 |
2 |
| 27 |
26020121 | SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. | 2015 Aug |
3 |
| 28 |
26164721 | Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations. | 2015 Jul |
1 |
| 29 |
26329790 | Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate Simvastatin. | 2015 Nov |
1 |
| 30 |
26367500 | Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid. | 2015 Dec |
2 |
| 31 |
26376374 | Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies. | 2015 Sep |
1 |
| 32 |
24263182 | The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. | 2014 Jan |
1 |
| 33 |
24322971 | Cardiovascular pharmacogenomics: expectations and practical benefits. | 2014 Mar |
1 |
| 34 |
24668570 | No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. | 2014 Jul |
6 |
| 35 |
24918167 | The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. | 2014 Oct |
2 |
| 36 |
24989890 | Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data. | 2014 Sep |
1 |
| 37 |
25563221 | Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients. | 2014 Mar 27 |
1 |
| 38 |
23263738 | Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. | 2013 Jun |
1 |
| 39 |
23469684 | Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. | 2013 Feb |
1 |
| 40 |
23579966 | Expanding role of pharmacogenomics in the management of cardiovascular disorders. | 2013 Jun |
2 |
| 41 |
23708174 | Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. | 2013 Jun |
1 |
| 42 |
23858814 | Simvastatin-lnduced nocturnal leg pain disappears with pravastatin substitution. | 2013 May-Jun |
1 |
| 43 |
24459608 | SLCO1B1 Polymorphisms and Statin-Induced Myopathy. | 2013 Dec 4 |
1 |
| 44 |
21243006 | Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. | 2012 Jun |
5 |
| 45 |
21819236 | Using genome-wide association studies to identify genes important in serious adverse drug reactions. | 2012 |
1 |
| 46 |
21928084 | SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. | 2012 Mar |
2 |
| 47 |
22382501 | Genetic determinants of response to cardiovascular drugs. | 2012 May |
1 |
| 48 |
22505549 | SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians. | 2012 Mar |
4 |
| 49 |
22524173 | Role of genetic factors in statins side-effects. | 2012 Sep |
1 |
| 50 |
22617227 | The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. | 2012 Jul |
1 |